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Introduction
Most drugs are organic or biologically derived compounds, and the pharmaceutical industry focuses on organic chemistry with some exceptions [1] . Metal-based therapeutics comprise only a small percentage of available drugs. After the discovery and successful clinical applications of the Pt-based anticancer drug cisplatin, however, research on metal-based drugs became increasingly more important. There is a growing interest in metal-containing drugs, and medicinal inorganic chemistry covering applications of metals in therapeutics and diagnostics is a field of increasing prominence [2] . The major advantage of metal-based over organic-based drugs is the ability to vary coordination 4 successful is redox activation, in which the active species is formed in a reductive cellular environment [5] .
Tumors are characterized by low oxygen concentration levels which give rise to a more reducing environment compared to normal tissue. The reductive microenvironment of hypoxic tumors results from insufficient formation of new blood vessels during growth [6] . Also, a large concentration of cellular reducing agents like glutathione is present in cancer cells, contributing to a reductive environment. Tumor hypoxia has been linked to unsuccessful treatments using chemotherapy and radiotherapy due to distance from blood vessels and resulting low oxygen levels [7] . Tumor cells that can survive in hypoxic conditions upregulate drug resistance genes [8] . Although hypoxia is considered a serious problem in cancer therapy, it can be exploited for therapeutic selectivity, since it differentiates cancerous and healthy tissue. One promising avenue is the development of bioreductive drugs that are selectively activated under such intracellular conditions. Literature known bioreductively activatable agents comprise quinones, nitroimidazoles, aromatic N-oxides, mustard nitrogens, and a few metal-containing compounds [8, 9] .
Metal compounds are to be delivered to the target environment in an inert oxidized state (without prior reduction), and metabolized when they reach the reductive environment of the cancer cell rendering the inactive compound cytotoxic. Three Pt(IV) and two Ru(III) compounds have already been in clinical trials -to date the most promising bioreductive pharmaceuticals based on metals [6] .
This review covers applications of metal-based drugs for anticancer applications using the redox-activated prodrug strategy. Electrochemical aspects of redox-activatable Pt and, particularly, Ru compounds have been reviewed in detail recently [6] . Thus, this review focuses on literature that has been published since then and electrochemical aspects will be touched only superficially. (2), and oxaliplatin (3) , and clinical use only in some Asian countries: neda-(4), loba-(5) and heptaplatin (6) .
Once in the cell, where the chloride concentration drops from about 100 mM in extracellular fluids to 4 mM, cisplatin is aquated by substitution of its chlorido ligands with water ligands. Only 1% (or less) of the administered cisplatin ends up binding to the biological target DNA, which results in apoptotic cell death. The majority of cisplatin reacts with proteins and low molecular weight biomolecules, especially with those containing sulfur.
This non-discriminate binding causes side-effects of cisplatin like nephrotoxicity [3] .
Carboplatin (2) displays a more tolerable toxicological profile due to the higher stability of the chelating 1,1-cyclobutanedicarboxylato ligand when compared to the chlorido ligands in cisplatin. No nephrotoxicity is observed [10] . Oxaliplatin (3) is also active against cancer cell lines that are resistant to cisplatin and carboplatin [10] .
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Clinical complications associated with the use of cisplatin, such as nephro-and neurotoxicity and the fact that only some tumors can be cured, might be overcome by using prodrugs with platinum in the more inert +IV oxidation state (Scheme 1) [2] . The administration of non-toxic Pt(IV) prodrugs that can be activated selectively by reduction at the tumor sites might reduce unwanted reactions with biomolecules and thus minimize undesired side-effects. Even oral administration is conceivable, since in contrast to the quite reactive Pt(II), Pt(IV) compounds are more stable in biological fluids. Degradation in the gastrointestinal tract is thus less likely, and the Pt(IV) prodrugs may reach the cellular target without prior transformation. Pt(IV) has a low-spin d 6 electron configuration and exhibits octahedral geometry. This configuration is relatively inert to substitution; reactions with biological nucleophiles are 7 thus disfavored compared to Pt(II) complexes, and the lifetime in biological fluids is expected to increase. It is not yet established, however, that Pt(IV) complexes survive long enough in vivo to be delivered to the tumor sites. The platinum compound could be also reduced extracellularly and enter the cell as Pt(II) (Scheme 1). As investigated by XANES (X-ray absorption near edge structure) analyses, the cellular distribution of Pt(IV) compounds 24 h after exposure is indeed similar to that of cisplatin. This result may indicate that the compound is readily reduced over that time period [11] . Microprobe SRIXE (synchrotron radiation-induced X-ray emission) is another excellent method for evaluating Pt compounds in whole and sectioned cells. This method has provided valuable insights into the distribution patterns and oxidation states of Pt drugs in cells [12] .
Variation of the axial ligands in Pt(IV) complexes affords a valuable strategy for altering their lipophilicity and redox potentials, factors that may affect the ability to enter tumor cells before being reduced to the active Pt(II) compound and, subsequently, the cytotoxicity. For a series of different Pt(IV) complexes which, upon reduction, yield the same Pt(II) species there was an 800-fold range in cytotoxicity [13] . Although the pharmacology of Pt(IV) compounds seems to depend strongly on the nature of the axial ligands, activity can be also influenced by the potency of the Pt(II) complex formed upon reduction [14] .
Lipophilic drugs are supposed to diffuse readily through cell membranes, thereby increasing their uptake. Lipophilicity, however, has to fall within an optimal window, otherwise the complex either becomes too insoluble in aqueous media or is trapped within the membrane. Platinum compounds with intermediate lipophilicity are therefore advantageous for cell uptake and anticancer activity [15] .
More electronegative ligands tend to destabilize Pt(IV) compounds. Most easily reduced are those having axial chlorido ligands, and the most difficult are compounds with hydroxido ligands [10, 16] [17] .
Potential reducing agents for Pt(IV) in the cell are glutathione [20] [21] [22] , for which E 0 = -240 mV at pH 7.0 [23] , ascorbate (vitamin C), NAD(P)H, and cysteine-containing proteins [14, 24] . Metallothionein, a protein consisting of 61 amino acids with 20 cysteine residues, is a potential binding and redox partner for Pt(IV). Increased metallothionein levels are proposed as a mechanism by which cells become resistant to platinum drugs [25] . Serum albumin, a small protein with a 35% cysteine content, also represents a potential binding partner for cisplatin as well as Pt(IV) compounds [19] .
Although Pt(IV) can be reduced by both extra-and intracellular reducing agents (Scheme 1), higher concentrations of these species are present within cells; e.g., for glutathione, the levels are 1-10 mM in cells vs. 2 µM in plasma [26] . Besides reducing Pt(IV) complexes efficiently, thiols at high concentrations can also coordinate to and deactivate the resulting Pt(II) species, thereby reducing their efficacy.
The DNA binding properties of Pt complexes of the type cis,trans,cis-[PtCl 2 L 2 (en)] correlate well with the reduction potentials; the more readily reduced complexes are better able to bind DNA [18] . Although reduction seems to be required for activity, and reactivity is enhanced in the presence of reducing agents [22, 27] , Pt(IV) complexes can apparently also bind directly to DNA (Scheme 1) [28] [29] [30] . Reduction of Pt(IV) has even been claimed to occur by DNA itself, either by the nucleobases or the sugars of the sugar-phosphate backbone [14] . Upon arrival at the target site, the kinetic preference of a Pt(IV) complex for reduction by, versus binding to, DNA is then the deciding factor [14] . These arguments, while intriguing, would benefit by isolation and identification of the DNA fragments that are oxidized in the process.
Correlations of Pt(IV)/Pt(II) redox potentials with biological activity have been explored within the context of quantitative structure-activity relationships (QSAR). Several Pt(IV) complexes with various equatorial and axial ligands were synthesized to develop a predictive QSAR model. Theoretical descriptors were included in this model together with physicochemical data like lipophilicity, reduction peak potential, and the number of oxygen atoms in the molecular formula of the ligand [31] . In vitro cytotoxicity could be predicted based on this QSAR model, but the actual effects in vivo still have to be verified, because others have not been able to correlate reduction potential with cytotoxicity across a large series of different Pt(IV) complexes [32] .
The effects of axial and carrier ligands on the reduction potential and cytotoxic properties of Pt(IV) complexes have also been investigated to define a relationship between reduction rate, redox potential, and in vitro cytotoxicity of Pt(IV) compounds. The reduction rates depended on the electronegativity and the steric hindrance of the axial and carrier ligands. Complexes carrying bulkier and more electron-withdrawing ligands were reduced more rapidly and showed higher reduction potentials. Reduction rates and the cytotoxicity of complexes with different carrier or axial ligands were correlated [17] .
As can be concluded from the above examples and other factors, the selection of drug candidates based on in vitro activity can be misleading. The most active species is usually chosen for animal studies, whereas the most inert species in vitro might actually show the highest activity in vivo [4] . It is therefore important that the Pt(II) species de- the platinated DNA from the excision repair machinery [34] . Such upregulation of HMGB1 has the potential to sensitize cells to cisplatin. Cytotoxicity in ER(+) cells increased by up to 2-fold when compared to ER(-) cells [35] .
For overcoming drug resistance, ethacrynic acid was coupled in another Pt(IV) construct termed ethacraplatin (8) . The cytosolic enzyme glutathione-S-transferase (GST) was inhibited by the two equivalents ethacrynic acid released per Pt(IV) upon reduction.
In three out of four cell lines the cytotoxicity was increased. After short incubation times (24 h) ethacraplatin was up to 2.5 times more effective than cisplatin as measured by
IC 50 values, whereas after 72 h both compounds displayed comparable cytotoxicity [36] . and apoptosis inducing factor is translocated to the nucleus [37] . Mitaplatin can thus efficiently target both nuclear DNA with released cisplatin and mitochondria with released DCA in cancer cells. The cytotoxicity of mitaplatin equals or exceeds that of most other Pt(IV) compounds and is comparable to that of cisplatin in a variety of cancer cell lines [38] .
Small peptides recognizable by cancer tissue-specific receptors, the integrins, have also been used as targeting moieties. In order to target cells expressing integrins on their surface, Pt(IV) was coupled to several small peptides (3-5 amino acids) containing RGD or NGR by either one or two amide linkages through either one or two succinato groups (10, R 1 = RGD, NGR, c(CRGDC), c(RGDfK)) [39] . Cytotoxicity was tested in several endothelial and human cancer cells. RGD-tethered Pt(IV) complexes were more cytotoxic than non-targeting Pt(IV) compounds and RGD tri-and pentapeptide moieties alone. NGR conjugates were less inhibitory than RGD counterparts, but were still more active than nonspecific Pt(IV)-peptide analogues.
Platinacyclobutane complexes (11) , in which biologically relevant molecules like thymidine, cholesterol, glucose, and proline (R 2 ), are linked to cyclobutane moiety in an equatorial position, have also been synthesized. The biocomponents were coupled to cyclopropylmethanol and then allowed to react with Zeise's dimer ([Pt(C 2 H 4 )Cl 2 ] 2 ) resulting in platinacycles. It is anticipated that the presence of the biomolecules would lead to increased water solubility and cancer targeting, but thus far there has been no evaluation of these compounds either in vitro or in vivo [40, 41] .
Pt(IV) compounds lacking biologically active ligands have also been quite successful in vitro. Four such octahedrally coordinated Pt(IV) complexes have even entered clinical trials, namely, tetra-(12), ipro-(13) and satraplatin (14, formerly JM-216, diacetatoamminedichlorido(cyclohexylamine)platinum(IV)) as well as LA-12 (15) . LA-12, however, failed in phase I. Tetraplatin could not be investigated further after phase I studies due to its high neurotoxicity. Iproplatin showed only limited success in phase II due to its low reactivity. Satraplatin, the first orally available Pt-based drug candidate, had to be abandoned recently in phase III [42] . Thus none of the platinum(IV) compounds has yet found its way to the clinics because of lower efficacy than cisplatin, variability in drug uptake, or the production of severe side-effects [6] . Satraplatin, although failing to provide an increase in overall survival above statistical significance when compared to cisplatin, was better tolerated and showed no signs of inducing nephrotoxicity [43] .
The initial success of the acetato complexes satraplatin (14) These results challenge the commonly held supposition that, upon reduction, Pt(IV) compounds derived from cisplatin and related Pt(II) complexes, only release their axial ligands; this assumption might have to be reassessed for Pt(IV) derivatives carrying axial acetate groups [44] .
The reduction of satraplatin (14) in extracts from three different cancer cell lines was monitored by 2D NMR spectroscopy. The cellular reduction rates followed the order A2780cisR > A2780 > HT-29, where HT-29 are colon cancer cells and A2780cisR is a cisplatin resistant cell line obtained from A2780 ovarian cancer cells by exposure to cisplatin. Reduction of satraplatin was not performed by low molecular weight (MW) antioxidants such as ascorbate and glutathione, but primarily by cellular components having MW > 3000 [44] ; the metalloproteins cytochrome c and hemoglobin in the presence of NADH were competent to reduce satraplatin [45] . The most rapid reduction occurred in A2780cisR cell extracts, perhaps due to its intrinsically elevated levels of glutathione [46] . 
Ruthenium
The biological activity of Ru compounds was first recognized in the 1950s [48] , and reports of their anticancer activity appeared in the 1960s [49] . Several Ru-based compounds show significant efficacy against various types of tumors in vivo [50] while having lower toxicity than cisplatin in vitro [51, 52] . The mechanism of action of these Ru(III) compounds remains unknown and their in vivo chemistry is ambiguous [52] . Although Ru(III), like Pt(IV), can be reduced by ascorbate or glutathione under physiological conditions, the resulting Ru(II) complexes maintain their octahedral ligand set (Scheme 3) [54] . The biological target of Ru compounds has not been discovered. DNA adducts can be formed by both NAMI-A and KP1019. The resulting Ru-DNA adducts alter the duplex conformation [61] . KP1019 can unwind and bend DNA [62] . As for Pt(II) compounds, sulfur-containing biomolecules might bind to reduced Ru(II) species before they reach nuclear DNA.
NAMI-A undergoes aquation reactions within minutes [54] , whereas KP1019 is more stable, and better taken up by cells. About half of the intracellular Ru delivered in the form of KP1019 appears in the nucleus, which is quite high by comparison to other metal complexes; only 10% of cisplatin accumulates within the nucleus [63] . Ru compounds not only target DNA but also proteins. KP1019 binds to transferrin [64] (Scheme 3), an Fe(III) transport protein, and is released from the protein as Ru(II) after reduction by ascorbate or glutathione [6] . Interference with the Fe metabolism may also be an explanation for the anticancer activity of Ru(III) complexes [54] . The antitumor activity of Ru(III) compounds is postulated to depend on its reduction to Ru(II), since an increase in NAMI-A anti-metastatic activity occurs in the presence of biological reductants [55] . The more readily reduced Ru(III) complexes are more cytotoxic [65] .
Transformations of Ru(III) complexes in mammalian cells have been monitored by XANES and EXAFS (X-ray absorption fine structure). It was concluded from these measurements that Ru(III) mainly binds to N-donors; however, gel filtration studies showed that Ru(III) was completely protein-bound [54] . A comparative study of a series of Ru(III) compounds using X-ray absorption spectroscopy (XAS) at the Cl K-edge and Ru L-edge revealed that the indazole ligand (In) in KP1019, a weak donor toward Ru, facilitates facile reduction [52] . As for Pt, the use of microprobe X-ray fluorescence might provide information about a potential Pt(IV)-like 'activation by reduction' [6] and clarify the role of transferrin in Ru(III) transport [53] .
Ru(II)/Ru(III) redox chemistry has been studied thoroughly as an aspect of the mechanism of action of Ru(III) prodrugs, recently reviewed [6] . The redox potentials of KP1019
and NAMI-A are 30 mV and 25 mV, respectively, vs. NHE. The redox potentials are tunable by modification of the azole ligand (In and Im, respectively) [6] .
These redox potential values reveal that NAMI-A and KP1019 can be reduced by glutathione and ascorbate under physiological conditions [66, 67] . As described in the introduction, in addition to providing reducing agents, cancer cells also harbor a hypoxic environment that promotes reduction and subsequent reactivity [52] . Increased levels of Ru-DNA adducts occurred when the O 2 partial pressure was low, indicating a greater amount of reduced, Ru(II), species [68] .
Ru(III) phosphane complexes in which the metal is coordinated by two P,O,O-tridentate
tris(o-anisyl) phosphane ligands are highly cytotoxic even in cisplatin-resistant cell lines [69] . Another construct involves NAMI A-type ligands conjugated through pyridyl or bipyridyl rings to yield Ru porphyrin conjugates (meso-4'-tetrapyridylporphyrin or meso-(p-bipyridyl-phenyl)porphyrin). The number of Ru fragments attached to the porphyrins ranged from 1 to 4. Conjugation of porphyrins to the Ru center was an attempt to obtain additive antitumor effects originating from the phototoxic and tumor-localizing properties of the porphyrin together with the cytotoxic properties of Ru(III) [70] . Thus far, however, the compounds have not been tested in vitro or in vivo.
An interesting conjugate was generated by coupling tamoxifen, a chemotherapeutic agent for patients with hormone-dependent breast cancer, with the organometallic Ru compound ruthenocene. This tamoxifen analog acts as an antiestrogen by competitive binding to the estrogen receptor in ER(+) breast cancer cells but not in ER(-) cells [71, 72] . This result is in contrast to that for the Fe analog ferrocifen (20) , which is active in both cell lines (vide infra). Since the structural differences between the Fe and Ru derivative are marginal, the different redox properties of the metal ions may be responsible for the different patterns of activity [71] .
Although Os belongs to the same group in the periodic 
Iron, Cobalt, Copper
Ferrocifen (20, Figure 4 ), like the corresponding Ru compound described above, is an organometallic derivative of the breast cancer drug tamoxifen. The ferrocene analog of hydroxytamoxifen, however, acts against both ER(+) and ER(-) human breast cancer cells, in contrast to the properties of hydroxytamoxifen alone [62, 78] . This behavior is surprising since the latter cells lack an obvious molecular target for tamoxifen. It can be concluded that the antiproliferative effect stems from the antiestrogenic effect of the tamoxifen moiety plus the cytotoxicity of the redox-active ferrocenyl group. Similarly, Au(I) has been claimed to protect phosphane ligands from oxidation in Au complexes like auranofin used for the treatment of rheumatoid arthritis [83] .
As in the Fe(III) complex, a tetradentate ligand, here tpa for tris(methylpyridyl)-amine, was combined with the hydroxamate to form the octahedral complex (22, Figure 5 ) [81, 84] . Increased cytotoxicity was observed for the prodrug in comparison to the inhibitor alone. In an in vivo study free marimastat and its Co complex inhibited tumor growth in the mammary fat pad in mice; but only the Co complex showed a statistically relevant difference compared to the control group. The complex was 2-3 times more effective in reducing the tumor growth than the MMP inhibitor alone. Both marimastat and its Co complex, however, potentiated metastasis when compared to controls [81] .
22 Nitrogen mustards are highly toxic due to their DNA cross-linking activity. In vivo they act unselectively, but can be deactivated by coordination to Co(III) and be released when reduction to Co(II) occurs in hypoxic tumor tissue, thereby reducing systemic toxicity [91, 95] .
Some nitrogen mustard ligands showed hypoxic selectivity in tumor cells [95] . The Co complex [Co(Meacac) 2 (DCE)] + (24, acac = acetylacetonate, DCE = N,N-bis(2-chloroethyl)ethylenediamine) had 20-times greater activity against hypoxic than oxic cancer cells [96] . In a series of Co acac complexes, the redox potential was of importance for hypoxic selectivity. The optimal value was -305 mV vs. NHE [96] . For 24, hypoxic selectivity did not rely on redox cycling, i. e. reoxidation by O 2 in oxic tissue, because reoxidation was too slow relative to ligand release [8, 85] .
Co(III) cyclen complexes having azachloromethylbenzindoline in the coordination sphere can be reduced under hypoxic conditions to release this agent, a potent DNA minor groove alkylator [92] .
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The chemistry of copper is attractive for the development of hypoxia selective drugs, because Cu has two oxidation states and the reduction potential in accessible within the cellular potential range [97] .
As for Co(III), Cu(II) complexes can be reduced to form Cu(I) complexes of low stability to release an active ligand. Furthermore, radioactive isotopes of Cu can be used, providing the combination of radiation therapy with bioreduction. For this purpose, the tirapazamine ligand has been suggested as a hypoxic cytotoxin for use with radioactive
Cu, combining the antitumor activity of the copper complex with its radioactivity, the Cu isotopes being 64 Cu or 67 Cu [98] . Radiolabelled 64 Cu complexes carried by bis(thiocarbazone) and bis(salicylaldimine) ligands showed hypoxic selectivity against
Chinese hamster ovary cancer cells [99] . Figure 6 ) exhibited good aqueous stability and, in vitro a 24-fold increased cytotoxicity under hypoxic conditions vs. oxic conditions. In aqueous solution, the redox behavior of the complex and its stability correlated well with hypoxia selectivity. The hypoxia selectivity is thought to originate from redox cycling in oxic tissue, similar to the behavior of Co(III) prodrugs described above (Scheme 5). Complexes 26 and 27, derived from the macrocyclic ligands cyclam and tacn, respectively, release the ligand independent 25 of O 2 partial pressure. This result indicates that bioreduction is less relevant for the latter systems, excluding their applications as prodrugs [89] . Figure 6 . Examples of Cu(II) complexes for releasing nitrogen mustards based on cyclen (25) , cyclam (26) , and tacn (27) .
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Scheme 5. Mechanism of prodrugs based on a Cu(II) nitrogen mustard cyclen complex (25) .
Copper diacetyl-bis(N 4 -methylthiosemicarbazone) is a promising compound for imaging hypoxic tissue based on PET using Cu radionuclides ( 60 Cu, 61 Cu, 62 Cu, and 64 Cu). A lower, i.e. more negative, reduction potential corresponded with increased selectivity of bioreduction and release of the ligand. Insight into the chemical and electronic properties underlying these previously observed structure-activity relationships was obtained recently by density functional theory (DFT) calculations [100] .
Cu(II) complexes with ligands based on 3-aminoquinoxaline-2-carbonitrile-N 1 ,N 4 -dioxide were developed to serve as selective hypoxic cytotoxins [101] . The complexes were evaluated under hypoxic and aerobic conditions in V79 cells. The complexes were equally low cytotoxic with the ligands under aerobic conditions, but more cytotoxic under hypoxic conditions [102] .
Quinoxaline-N 1 ,N 4 -dioxides themselves are bioreductively activatable drugs. However, they exhibit low aqueous solubility and a short half life [103] . Their vanadyl complexes VOL 2 , with L being a quinoxaline-N 1 ,N 4 -dioxide ligand, however, showed improved solubility and greater cytotoxicity than the free quinoxaline ligands, with high hypoxia selectivity [104] .
Pyrophosphate-bridged binuclear complexes of Cu(II) display low nanomolar toxicity against adriamycin-resistant ovarian cancer cells. The complexes were tested in glutathione assays to simulate cellular conditions. Cu(I) was formed in this reductive environment and the system produced hydrogen peroxide from molecular oxygen, producing oxidative stress. The generation of oxidative stress might explain the high cytotoxicity of this class of coordination compounds [105] .
Nanobased Drug Delivery Systems
Delivery systems can mediate transport of drug molecules to desired cell populations. In one manifestation of this strategy, Pt(IV) was attached to single-walled carbon nanotubes (SWNT) for shuttling into cells (28, Figure 7 ). Such soluble functionalized SWNTs nanotubes cross the cell membrane by clathrin-dependent endocytosis. A substantial increase in cytotoxicity was obtained when compared to cisplatin and the untethered Pt(IV) complex. In one experiment, the SWNT "longboat" carried 65 Pt "passengers" as determined by atomic absorption spectroscopy [106] . For targeting of folate receptors on cancer cells, the Pt(IV) prodrug was also coupled to folate (29) by using a bisuccinate precursor, Pt(succ) 2 , Figure 7 . One carboxyl group allowed coupling to folate via an amino linker, while the other allowed tethering to the aminated nanotube surface.
The toxicity in cell lines expressing the folate receptor increased by up to 9-fold by comparison to cisplatin [107] .
Gold nanoparticles have also been used as delivery systems for potentially therapeutic antisense oligonucleotides as well as Pt(IV) via covalent attachment (30) . The nanoparticles were functionalized with thiolated 28mer oligonucleotides containing a terminal dodecyl amine for conjugation. The Pt(IV) complex Pt(succ) (Figure 7 ) was tethered to the amino-functionalized DNA-Au-NP surface by forming an amide linkage [108] . The constructs showed high levels of cellular uptake in different cell types and higher cytotoxicity when compared to cisplatin and the Pt(IV) precursor Pt(succ).
Gold nanorods, on the other hand, are even more promising vehicles than gold nanoparticles due to longer circulation times when compared to the spherical particles.
PEGylated nanorods were loaded with disuccinato Pt(IV) (Pt(succ) 2 , 31, Figure 7 ). Cytotoxicity in HeLa, A549, and MCF7 cells was increased by up to 66-fold when compared to cisplatin. Cytotoxicity could be correlated with Pt uptake as measured by ICP-MS [109] .
Better protection of the Pt(IV) prodrug can potentially be provided by encapsulation into particles as opposed to tethering on their surface. Encapsulation protects the prodrug but also can ameliorate unwanted side-effects of the drug. Cisplatin itself shows only low loading efficiency (< 1 wt%) within the hydrophobic interiors of a polymer [110] , but an increase of internalization into nanoparticles could be achieved by using a hydro- loaded nanoparticles (33) . The nanoparticles were of sub-100 nm size and exhibited a cisplatin loading yield of 1.1 wt%. Due to the acid-labile hydrazone bond, the system showed acid-responsive drug release kinetics. The ability to kill ovarian cancer cells was enhanced when compared to that of cisplatin [113] .
A silica shell coating of coordination polymer nanoparticles based on Pt(succ) 2 increased half-release time for Pt by factor 9 -from 1 h for the uncoated Pt loaded polymer to 9 h. Cytotoxicity was similar to that of cisplatin in breast cancer cells. Upon conjugation of integrin-targeting peptides c(RGDfK), in vitro toxicity against colon cancer cells could be slightly increased in comparison to cisplatin [114] .
Lastly, ethoxysuccinato Pt(IV), the prodrug also used for coupling to SWNT in 28, was allowed to react postsynthetically with a dispersion of amino functionalized ironcarboxylate nanoscale metal-organic frameworks. Once Pt was loaded into the framework, the particles were coated with silica. The resulting material was then evaluated for its cytotoxicity in HT-29 cells and found to be slightly less cytotoxic than cisplatin. In order to increase the cytotoxicity, the silica shell was functionalized with a silyl derivative of c(RGDfK) (34) . As in the other examples described above, it was thereby armed for targeting integrins, over-expressed in many anigiogenic tumors. Cytotoxicity was thus increased, approaching that of cisplatin [115] . XANES, X-ray Absorption Near Edge Structure; XAS, X-ray absorption spectroscopy.
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